While apixaban was linked to more total major bleeds, rates of fatal and intracranial hemorrhage were similar to aspirin.

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

MADRID, Spain—For patients who experience venous thromboembolism (VTE) provoked by surgery, immobility, or other factors and who face ongoing risk factors, 12 months of low-intensity apixaban (Eliquis ...